Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pooled Analysis of Trabectedin Efficacy in Myxoid/Round Cell Liposarcoma from Three Prospective Clinical Trials.

Cancers·2026
Same author

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Correction: ASO Visual Abstract: Well‑Differentiated Liposarcoma of the Psoas Muscle: A Distinct Anatomic Subset with Highly Favorable Outcomes.

Annals of surgical oncology·2026
Same author

LPAR4 mediates resistance to interferon-induced stress in soft tissue sarcoma.

Science advances·2026
Same author

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.

Cancer research communications·2026
Same author

Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States.

bioRxiv : the preprint server for biology·2026
Same journal

Vaccination practice and safety in children with special health care needs: A retrospective study of 1278 children.

Human vaccines & immunotherapeutics·2026
Same journal

Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology.

Human vaccines & immunotherapeutics·2026
Same journal

Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan's pediatric National Immunization Program and impacts of a delayed implementation.

Human vaccines & immunotherapeutics·2026
Same journal

Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trial.

Human vaccines & immunotherapeutics·2026
Same journal

Randomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants.

Human vaccines & immunotherapeutics·2026
Same journal

Determinants of HPV vaccination acceptance among young adult women in Japan's catch-up generation: A cross-sectional study.

Human vaccines & immunotherapeutics·2026
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.5K

Potential for immunotherapy in soft tissue sarcoma.

William W Tseng1, Neeta Somaiah, Edgar G Engleman

  • 1a Section of Surgical Oncology; Division of Upper GI/General Surgery; Department of Surgery ; University of Southern California; Keck School of Medicine ; Los Angeles , CA USA.

Human Vaccines & Immunotherapeutics
|January 28, 2015
PubMed
Summary
This summary is machine-generated.

Immunotherapy shows promise for soft tissue sarcomas (STS), rare cancers with limited treatment options. Research into STS immunology is crucial for developing effective, subtype-specific immunotherapeutic strategies.

Keywords:
adoptive cell therapycancer vaccinesimmune checkpoint blockadeimmunotherapysoft tissue sarcoma

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.4K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K

Related Experiment Videos

Last Updated: Apr 18, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.5K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.4K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Soft tissue sarcomas (STS) are rare, heterogeneous mesenchymal tumors.
  • A significant proportion of patients experience recurrent or metastatic disease despite optimal treatment.
  • Current therapeutic strategies for advanced STS are limited.

Purpose of the Study:

  • To review the current status and potential of immunotherapy for soft tissue sarcomas.
  • To explore the biological rationale for immunotherapy in STS.
  • To identify future research directions for STS immunotherapy.

Main Methods:

  • Review of existing literature on immunotherapy in STS.
  • Analysis of data from human studies involving cancer vaccines, adoptive cell therapy, and immune checkpoint blockade.
  • Discussion of STS biology relevant to immunotherapeutic approaches.

Main Results:

  • Immunotherapy has shown significant progress in other solid tumors.
  • STS exhibit biological features, such as fusion proteins and cancer testis antigens, that support an immunotherapeutic approach.
  • Early data from human studies on various immunotherapy modalities in STS are emerging.

Conclusions:

  • There is a strong scientific rationale for pursuing immunotherapy in soft tissue sarcomas.
  • Further investigation into STS immunology is essential.
  • Development of logical, subtype-specific immunotherapeutic strategies is needed for improved patient outcomes.